MKI67 and breast carcinoma: The overall summary results of pooled pCR outcome of NAC-treated Asian breast cancer patients of this study can be found in Table 1 whereby the favoured outcome for molecular subtypes with various NAC treatments were HER2E, TNBC, and Luminal B. The favoured outcome for biomarkers across different NAC treatments was ER−, PR−, HR− and high ki67.